Encorafenib with binimetinib for treating metastatic BRAF V600 mutant non-small-cell lung cancer

Encorafenib in combination with binimetinib is in development for the treatment of BRAF V600E mutant metastatic non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Metastatic cancer means it has spread around the body from where it started in the lungs. The BRAF gene encodes for a protein (called BRAF) which is involved in stimulating cell division. A common mutation to this gene is ‘V600E’. This abnormal form of BRAF plays a role in the development of the cancer by allowing uncontrolled division of the tumour cells. There is currently no recommended treatment options for this specific mutation in NSCLC, highlighting the need for a therapy.